Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
1,400 | 1,400 | 16,370,679 | 1,623 | Methods of treating chin retrusion in a subject by increasing a glabella-subnasale-pogonion (G-Sn-Pog) facial angle of the subject are provided, which may include injecting a first volume of a dermal filler into a pogonion, injecting a second volume of a dermal filler into a mentum, and/or injecting a third volume of t... | 1. A method of treating chin retrusion in a subject by increasing a glabella-subnasale-pogonion (G-Sn-Pog) facial angle of the subject, the method comprising:
injecting a first volume of a composition comprising a dermal filler into a pogonion; injecting a second volume of the dermal filler into a mentum; and injecting... | Methods of treating chin retrusion in a subject by increasing a glabella-subnasale-pogonion (G-Sn-Pog) facial angle of the subject are provided, which may include injecting a first volume of a dermal filler into a pogonion, injecting a second volume of a dermal filler into a mentum, and/or injecting a third volume of t... | 1,600 |
1,401 | 1,401 | 16,059,522 | 1,613 | A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting... | 1-15. (canceled) 16. A medical device, comprising:
an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises:
a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof, and
a local anesthetic dose-extending component selected from... | A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting... | 1,600 |
1,402 | 1,402 | 14,513,735 | 1,615 | The present invention relates to water treatment, In one example, there is provided a method of treating an aqueous system comprising dissolved solids to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method includes adding treatment agents to said... | 1. A method of treating an aqueous system comprising dissolved solids to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein, wherein the method comprises adding treatment agents to said aqueous system and wherein said treatment agents comprise:
(a) a phosph... | The present invention relates to water treatment, In one example, there is provided a method of treating an aqueous system comprising dissolved solids to inhibit growth of one or more micro-organisms therein and/or to reduce the number of live micro-organisms therein. The method includes adding treatment agents to said... | 1,600 |
1,403 | 1,403 | 14,625,086 | 1,646 | The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are ... | 1-20. (canceled) 21. A method for detecting thyroid hormone blocking immunoglobulin (TBI) in a biologic sample, comprising
i) combining:
a) transgenic cells stably transfected with
a first nucleic acid sequence which encodes a reporter wherein the first nucleic acid is operably linked to a cAMP-inducible promoter, and ... | The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are ... | 1,600 |
1,404 | 1,404 | 14,914,792 | 1,654 | Methods of treating bacterial infections in a subject using oritavancin, including bacteremia, osteomyelitis and endocarditis, are disclosed. | 1. A method of treating bacteremia in a subject, comprising administering a therapeutically-effective amount of oritavancin or a salt thereof to a subject having bacteremia, thereby treating bacteremia in a subject. 2. The method of claim 1, wherein (i) the bacteremia was resistant to previous antibiotic treatment, (ii... | Methods of treating bacterial infections in a subject using oritavancin, including bacteremia, osteomyelitis and endocarditis, are disclosed.1. A method of treating bacteremia in a subject, comprising administering a therapeutically-effective amount of oritavancin or a salt thereof to a subject having bacteremia, there... | 1,600 |
1,405 | 1,405 | 16,780,365 | 1,612 | Provided are methods for labeling a pharmaceutical product to indicate the origin, and/or intended recipient, and/or a predetermined characteristic (e.g. geographic location) of an intended recipient of the pharmaceutical product. The methods include incorporating certain pharmaceutically inactive marker substances int... | 1. A method of labeling a pharmaceutical product, the method comprising incorporating into the pharmaceutical product during manufacture a unique marker profile comprising one or more pharmaceutically inactive marker substances, wherein the one or more marker substances comprise one or more polyethylene glycols. 2. The... | Provided are methods for labeling a pharmaceutical product to indicate the origin, and/or intended recipient, and/or a predetermined characteristic (e.g. geographic location) of an intended recipient of the pharmaceutical product. The methods include incorporating certain pharmaceutically inactive marker substances int... | 1,600 |
1,406 | 1,406 | 14,130,995 | 1,627 | The method of the present application is directed towards a method for suppressing an allergic response in response to an allergic trigger. This method comprises the following steps; applying, topically, to an affected area an effective amount of a minocycline composition so that the minocycline composition contacts th... | 1. A method for suppressing an allergic response in response to an allergic trigger in an affected area, the method comprising:
applying, topically, to the affected area an effective amount of a minocycline composition so that the minocycline composition contacts the affected area for an effective amount of time, and r... | The method of the present application is directed towards a method for suppressing an allergic response in response to an allergic trigger. This method comprises the following steps; applying, topically, to an affected area an effective amount of a minocycline composition so that the minocycline composition contacts th... | 1,600 |
1,407 | 1,407 | 14,649,796 | 1,635 | In accordance with an embodiment of the invention, a system and method is provided for determining a probability of a progeny having one or more phenotypes Ph j each associated with a single gene Q j . A score sip may be assigned to each allele hip at a plurality of genetic loci (i) in a haploid genome profile H p of... | 1. A method of determining a probability of a progeny having one or more phenotypes Phj each associated with a single gene Qj, the method implemented by a computer processor executing program instructions, the method comprising the steps of:
a. assigning a score si p to each allele hi p at a plurality of genetic loci (... | In accordance with an embodiment of the invention, a system and method is provided for determining a probability of a progeny having one or more phenotypes Ph j each associated with a single gene Q j . A score sip may be assigned to each allele hip at a plurality of genetic loci (i) in a haploid genome profile H p of... | 1,600 |
1,408 | 1,408 | 16,109,127 | 1,654 | The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions. | 1-15. (canceled) 16. A method of treating dry eye disease, the method comprising topically administering twice daily to an eye of a human with dry eye disease a composition comprising about 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane, wherein said composition is substantially free of water and is subs... | The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.1-15. (can... | 1,600 |
1,409 | 1,409 | 14,115,362 | 1,616 | An agricultural oil-based suspension formulation comprising an active ingredient suspended in finely divided form in an oil; and at least one surfactant selected from a polyalkylene glycol-fatty acid condensate or a polyalkylene glycolether fatty acid condensate formed from a reaction between a compound having Structur... | 1. An agricultural oil-based suspension formulation comprising an active ingredient suspended in finely divided form in an oil; and at least one surfactant selected from a polyalkylene glycol-fatty acid condensate or a polyalkylene glycolether fatty acid condensate formed from a reaction between a compound having Struc... | An agricultural oil-based suspension formulation comprising an active ingredient suspended in finely divided form in an oil; and at least one surfactant selected from a polyalkylene glycol-fatty acid condensate or a polyalkylene glycolether fatty acid condensate formed from a reaction between a compound having Structur... | 1,600 |
1,410 | 1,410 | 15,870,344 | 1,658 | Conjugates of a cholinesterase moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods... | 1. A conjugate comprising a residue of a cholinesterase moiety covalently attached to a water-soluble polymer, wherein the residue of the cholinesterase moiety is covalently attached to the water-soluble polymer through a cysteine residue within the residue of the cholinesterase moiety. 2. A conjugate comprising a resi... | Conjugates of a cholinesterase moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods... | 1,600 |
1,411 | 1,411 | 15,371,977 | 1,617 | The invention relates to a bracelet or strap, in particular a watch band, comprising at least one organic material based portion intended to be placed in contact with the user's skin, said organic material containing at least one functional agent, such as an antibacterial agent. According to the invention, said organic... | 1. A bracelet or strap, comprising at least one organic material, said organic material containing at least one functional agent, wherein said organic material also contains at least one cosmetic agent for skin arranged to be able to be in contact with the user's skin when the bracelet or strap is worn. 2. The bracelet... | The invention relates to a bracelet or strap, in particular a watch band, comprising at least one organic material based portion intended to be placed in contact with the user's skin, said organic material containing at least one functional agent, such as an antibacterial agent. According to the invention, said organic... | 1,600 |
1,412 | 1,412 | 15,857,145 | 1,618 | Drift reduction adjuvant composition and agricultural sprays containing such agricultural compositions contain water, a Newtonian responding polymer such as guar gum, an emulsifier such as a polyoxyethylene sorbitan emulsifier, and an oil. When the agricultural spray containing the drift reduction adjuvant composition ... | 1. A drift reduction adjuvant composition, comprising:
water; guar gum; a polyoxyethylene sorbitan emulsifier; and a seed oil. 2. The drift reduction adjuvant composition of claim 1, wherein the polyoxyethylene sorbitan emulsifier comprises one or more of: polyoxyethylene sorbitan fatty acid ester, polyoxyethylene 20 s... | Drift reduction adjuvant composition and agricultural sprays containing such agricultural compositions contain water, a Newtonian responding polymer such as guar gum, an emulsifier such as a polyoxyethylene sorbitan emulsifier, and an oil. When the agricultural spray containing the drift reduction adjuvant composition ... | 1,600 |
1,413 | 1,413 | 15,318,518 | 1,628 | The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders. | 1-30. (canceled) 31. A method for treating dyskinesia or reducing abnormal involuntary movements in movement disorders, comprising:
administering to a subject in need thereof a pharmaceutical composition comprising 6-hydroxybuspirone (6-OH-Busp) or a pharmaceutically acceptable derivative thereof. 32. The method of cla... | The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.1-30. (canceled) 31. A method for treating dyskinesia or reducing abnormal involuntary movements in movement disorders, comprising... | 1,600 |
1,414 | 1,414 | 15,094,542 | 1,619 | Pressurized compositions propelled by a pressurizing component (preferably a propellant such as compressed gas) and further including at least one active ingredient, at least one high molecular weight nonionic surfactant, and water which is a major component of the composition and is at least substantially ion-free and... | 1. A pressurized article comprising
(a) a pressurized container for storing and dispensing a composition, wherein said container includes a spray nozzle and a plastic body for containing said composition; and (b) said composition for storing in and dispensing from said container comprising
(i) at least one pressurizing... | Pressurized compositions propelled by a pressurizing component (preferably a propellant such as compressed gas) and further including at least one active ingredient, at least one high molecular weight nonionic surfactant, and water which is a major component of the composition and is at least substantially ion-free and... | 1,600 |
1,415 | 1,415 | 14,761,824 | 1,655 | We found that Andrographolide binds to GSK-3β:
In so doing, andrographolide prevents changes in neuropathology in an Alzheimer's model, reducing Amyloid-β peptide levels, changing the ontogeny of hippocampus and cortex amyloid plaques, and reducing tau phosphorylation around Amyloid-β. Andrographolide recovers sp... | 1. Administering to human diagnosed with dementia, a therapeutically effective amount of a compound of Formula (I):
wherein
R1 is selected from the group consisting of hydrogen, alkyl or hydroxyl,
R2 is selected from the group consisting of hydroxyalkyl or alkyl-O-L1, wherein L1 is a carbohydrate moiety,
R3 ... | We found that Andrographolide binds to GSK-3β:
In so doing, andrographolide prevents changes in neuropathology in an Alzheimer's model, reducing Amyloid-β peptide levels, changing the ontogeny of hippocampus and cortex amyloid plaques, and reducing tau phosphorylation around Amyloid-β. Andrographolide recovers sp... | 1,600 |
1,416 | 1,416 | 13,072,084 | 1,632 | The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents... | 1. A method for treating inflammation in a subject having a condition, the method comprising selecting cells that have a desired potency for modulating microglia activation, assaying the selected cells for the desired potency, and administering the cells having the desired potency to the subject, in a therapeutically e... | The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents... | 1,600 |
1,417 | 1,417 | 14,752,511 | 1,634 | Provided herein are methods for determining if a urine sample comprises synthetic urine, methods for matching a urine sample to a subject, and methods for amplifying DNA. Also provided are kits that include a set of at least 3 pairs of a pre-amplification forward and reverse primer, where each pair of pre-amplification... | 1. A method of determining if a urine sample comprises synthetic urine comprising:
(a) providing a urine sample from a subject; (b) enriching the urine sample for mammalian cells, if present; (c) isolating any genomic DNA from the enriched sample of step (b) to form an isolated genomic DNA test sample; (d) adding to th... | Provided herein are methods for determining if a urine sample comprises synthetic urine, methods for matching a urine sample to a subject, and methods for amplifying DNA. Also provided are kits that include a set of at least 3 pairs of a pre-amplification forward and reverse primer, where each pair of pre-amplification... | 1,600 |
1,418 | 1,418 | 15,167,866 | 1,653 | Mass spectrometric methods are described for determining the amount of analyte in a sample collected by a microsampling device. Provided herein are methods directed to quantitating the amount of an analyte in a sample by extracting an analyte from a sample collected by a microsampling device, purifying the sample by li... | 1. A method for determining the amount of an analyte in a sample by mass spectrometry, the method comprising:
(a) extracting an analyte from a sample collected by a microsampling device; (b) ionizing the analyte to generate one or more ions detectable by mass spectrometry; and (c) determining the amount of the one or m... | Mass spectrometric methods are described for determining the amount of analyte in a sample collected by a microsampling device. Provided herein are methods directed to quantitating the amount of an analyte in a sample by extracting an analyte from a sample collected by a microsampling device, purifying the sample by li... | 1,600 |
1,419 | 1,419 | 16,073,778 | 1,633 | The invention pertains to therapies that require gene editing, and more specifically to non-viral methods for in vivo delivery of endonuclease reagents to specific tissues or cells. According to the invention, the endonuclease reagents are encapsulated into micelle structures of 50 to 150 nm diameter for intravenous in... | 1) A method for encapsulating an endonuclease reagent, comprising the steps of:
a) Engineering a endonuclease reagent under RNA form; b) Complexing said endonuclease reagent with at least one biodegradable matrix comprising at least a core hydrophobic domain and a proximal polar domain to favor interactions with water ... | The invention pertains to therapies that require gene editing, and more specifically to non-viral methods for in vivo delivery of endonuclease reagents to specific tissues or cells. According to the invention, the endonuclease reagents are encapsulated into micelle structures of 50 to 150 nm diameter for intravenous in... | 1,600 |
1,420 | 1,420 | 15,840,283 | 1,656 | A nanoparticle (for example, quantum dot) serves as a substrate for immobilizing enzymes involved in consecutive reactions as a cascade. This results in a significant increase in the rate of catalysis as well as final product yield compared to non-immobilized enzymes. | 1. An enzymatic cascade cluster comprising:
a plurality of nanoparticles associated together as a cluster, wherein each nanoparticle is bound to a plurality of enzymes configured as an enzymatic cascade wherein the product of a first enzyme is the substrate of a second enzyme and so forth; wherein the enzymatic cascade... | A nanoparticle (for example, quantum dot) serves as a substrate for immobilizing enzymes involved in consecutive reactions as a cascade. This results in a significant increase in the rate of catalysis as well as final product yield compared to non-immobilized enzymes.1. An enzymatic cascade cluster comprising:
a plural... | 1,600 |
1,421 | 1,421 | 16,306,113 | 1,613 | The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radi... | 1. A medicament containing sclareolide for use in the treatment, prevention and/or amelioration of hyperpigmentation. 2. The medicament of claim 1, wherein the hyperpigmentation is induced by the radiation of sunlight. 3. The medicament of claim 2, wherein the hyperpigmentation is induced by the radiation of visible li... | The present invention belongs to the fields of pharmaceuticals and cosmetics, and concerns on the one hand a medicament for the inhibition of and refers also on the cosmetic, non-therapeutic use for the treatment of hyperpigmentation, particularly induced by sun light radiation, preferably induced by visible light radi... | 1,600 |
1,422 | 1,422 | 15,610,267 | 1,646 | The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administeri... | 1. A method for reducing pruritus associated with atopic dermatitis (AD) in a patient, the method comprising:
(a) selecting a patient with moderate-to-severe atopic dermatitis, wherein the patient exhibits a Pruritus Numeric Rating Scale (NRS) score ≧5 and/or a 5-D Pruritus score ≧18; and (b) administering to the patie... | The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administeri... | 1,600 |
1,423 | 1,423 | 15,603,279 | 1,654 | Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The ... | 1. A method for treating chronic kidney disease-mineral bone disorder (CKD-MBD) characterized by soft tissue calcification in a subject, comprising:
administering to the subject a composition comprising a therapeutically effective amount of a calcimimetic having a sequence Ac-c(C)arrrar-NH2 (SEQ ID NO:3) or a pharmaceu... | Methods for treating subjects suffering from chronic kidney disease-mineral and bone disorder or other disorders resulting in primary or secondary hyperparathyroidism are described. The methods are effective in reducing serum parathyroid hormone (PTH) levels and calcium levels in patients who undergo hemodialysis. The ... | 1,600 |
1,424 | 1,424 | 14,942,592 | 1,631 | The disclosed computerized system and method facilitates predicting the onset of diabetes or symptom progression in those patients already suffering from the disease. The computerized system and method applies steps to segment the population by predefined member characteristics. Once segmented, the computerized system ... | 1. A method for predicting the onset of diabetes in a population without diabetes comprising:
receiving health related patient data from a plurality of sources; performing an extraction process upon the received data to extract features that describe at least one patient; processing the extracted data using a summariza... | The disclosed computerized system and method facilitates predicting the onset of diabetes or symptom progression in those patients already suffering from the disease. The computerized system and method applies steps to segment the population by predefined member characteristics. Once segmented, the computerized system ... | 1,600 |
1,425 | 1,425 | 14,240,273 | 1,644 | The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monom... | 1-19. (canceled) 20. A method for treating or preventing an angiogenesis-related disease in a patient in the need thereof, comprising administering to the patient a therapeutically effective dose of a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human co... | The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monom... | 1,600 |
1,426 | 1,426 | 16,062,151 | 1,612 | Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of ... | 1. An oral care composition comprising:
at least one phosphate/acrylate copolymer; at least one cationic antibacterial agent; at least one synthetic anionic linear polycarboxylate polymer; at least one surfactant; and zinc lactate. 2. The oral care composition according to claim 1, wherein the at least one cationic ant... | Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of ... | 1,600 |
1,427 | 1,427 | 15,766,517 | 1,612 | An oral care composition comprising at least one metal phosphate chosen from stannous phosphate, magnesium phosphate or aluminum phosphate; and at least one fluoride ion source. The at least one phosphate is added to the oral care composition as a preformed salt. Methods of administering the oral care composition to a ... | 1. An oral care composition, comprising:
at least one metal phosphate chosen from stannous phosphate, magnesium phosphate or aluminum phosphate, wherein the at least one phosphate is added to the oral care composition as a preformed salt; and at least one fluoride ion source. 2. The oral care composition of claim 1, wh... | An oral care composition comprising at least one metal phosphate chosen from stannous phosphate, magnesium phosphate or aluminum phosphate; and at least one fluoride ion source. The at least one phosphate is added to the oral care composition as a preformed salt. Methods of administering the oral care composition to a ... | 1,600 |
1,428 | 1,428 | 15,839,491 | 1,623 | The invention provides methods of reducing inflammation and improving the catabolic/anabolic state to promote healing of the cartilage in a joint by providing an oral dosage of either an anthocyanin or an anthocyanidin or their metabolites or a combination thereof. The treatment can occur before surgery, injury or infl... | 1. A method of treating osteoarthritis in a patient having an osteoarthritic joint, comprising orally administering a therapeutically effective amount of PCA to the patient;
wherein the therapeutically effective amount elicits an osteoarthritis disease modifying response comprising:
decreased inflammation and an altere... | The invention provides methods of reducing inflammation and improving the catabolic/anabolic state to promote healing of the cartilage in a joint by providing an oral dosage of either an anthocyanin or an anthocyanidin or their metabolites or a combination thereof. The treatment can occur before surgery, injury or infl... | 1,600 |
1,429 | 1,429 | 16,288,571 | 1,654 | Provided herein are water soluble salts of Formula I, wherein R 1 , A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same. | 1. A compound having Formula I,
wherein
M is Li, Na, or K,
or M is SrX, MgX, CaX or ZnX, wherein X is a monovalent anion of Formula I-Acid;
A is a bond, or
A represents a monopeptide or dipeptide linker, wherein the monopeptide or dipeptide is comprised of one or two amino acid units, each independently selec... | Provided herein are water soluble salts of Formula I, wherein R 1 , A, and M are defined herein. Also provided herein are methods of preparing the salts of Formula I and methods of using the same.1. A compound having Formula I,
wherein
M is Li, Na, or K,
or M is SrX, MgX, CaX or ZnX, wherein X is a monovalent... | 1,600 |
1,430 | 1,430 | 15,858,237 | 1,611 | The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; a... | 1. A cosmetic composition comprising:
at least 6 to about 25 wt. % of free glycolic acid and/or a salt thereof, provided that the cosmetic composition comprises at least 6 wt. % of free glycolic acid; about 5 to about 40 wt. % of at least one non-silicone fatty compound; about 0.1 to about 20 wt. % of at least one emul... | The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; a... | 1,600 |
1,431 | 1,431 | 15,497,640 | 1,611 | Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores... | 1. A method of reducing contamination by one or more toxins in a biological substance, said method comprising:
a. contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of... | Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores... | 1,600 |
1,432 | 1,432 | 15,166,339 | 1,619 | Provided, among other things, is a packaged condom comprising: a sealed package; within the package, an polyisoprene condom; and within the package and substantially coating the condom, a lubricant comprising solvent and one or more sensation-providing agents comprising one or more of vanillyl butyl ether, menthyl lact... | 1. A packaged condom comprising:
a sealed package; within the package, a synthetic polyisoprene condom; and within the package and substantially coating the condom, a lubricant comprising solvent and one or more sensation-providing agents comprising one or more of vanillyl butyl ether, menthyl lactate, and menthol, whe... | Provided, among other things, is a packaged condom comprising: a sealed package; within the package, an polyisoprene condom; and within the package and substantially coating the condom, a lubricant comprising solvent and one or more sensation-providing agents comprising one or more of vanillyl butyl ether, menthyl lact... | 1,600 |
1,433 | 1,433 | 15,238,408 | 1,617 | Liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery. | 1. A liquid formulation comprising:
sodium picosulfate; magnesium citrate; and at least one precipitation inhibitor, wherein the precipitation inhibitor is a carboxylic acid, an ammonium salt or a soluble anionic polymer; wherein the precipitation inhibitor is malonic acid or tartaric acid if the formulation does not c... | Liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.1. A liquid formulation comprising:
sodium picosulfate; magnesium citrate; and at least one precipitation in... | 1,600 |
1,434 | 1,434 | 14,442,662 | 1,617 | The present invention relates to shaped articles which are suitable for controlling Varroa mites in bees. | 1. A solid shaped article5 of a polyvinyl chloride matrix comprising
0.1 to 30% by weight of an acaricidal active substance,.
1 to 30% by weight of a glycerol ester or propylene glycol ester with C8-C12-fatty acids, and
optionally an adjuvant or additive,
wherein the shaped article has a thickness from 0.5 to 20 mm and... | The present invention relates to shaped articles which are suitable for controlling Varroa mites in bees.1. A solid shaped article5 of a polyvinyl chloride matrix comprising
0.1 to 30% by weight of an acaricidal active substance,.
1 to 30% by weight of a glycerol ester or propylene glycol ester with C8-C12-fatty acids,... | 1,600 |
1,435 | 1,435 | 15,579,030 | 1,613 | The present inventions concerns use of a certain methoxyacrylate compound to control mosquitoes, and vector control solutions comprising a defined methoxyacrylate compound, in particular the invention relates to a substrate, to a composition, for controlling mosquitoes comprising a defined methoxyacrylate compound, and... | 1. A method of controlling mosquitos, the method comprising: applying to a mosquito or to a locus of interaction of a mosquito, one or more methoxyacrylate compounds selected from Table 1 below:
TABLE 1
Compound
no.
1
2
3
4
... | The present inventions concerns use of a certain methoxyacrylate compound to control mosquitoes, and vector control solutions comprising a defined methoxyacrylate compound, in particular the invention relates to a substrate, to a composition, for controlling mosquitoes comprising a defined methoxyacrylate compound, and... | 1,600 |
1,436 | 1,436 | 16,377,465 | 1,641 | The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subj... | 1-17. (canceled) 18. A method for determining an increased risk of an apparently healthy subject, preferably a human, for suffering from an adverse event, comprising:
providing a sample from said subject; determining the level of procalcitonin (PCT) or of a fragment thereof in said sample; and determining whether said ... | The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subj... | 1,600 |
1,437 | 1,437 | 14,571,781 | 1,611 | Described herein are an aspirin or active aspirin derivative and a COX-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the COX-2 i... | 1. A method of sequentially administering an aspirin or active aspirin derivative and a COX-2 inhibitor for partitioned absorption, at least one of which has an enteric or partial enteric coating for bioabsorption in a patient's small intestine or colon. 2. The method of claim 1, wherein the COX-2 inhibitor has the ent... | Described herein are an aspirin or active aspirin derivative and a COX-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the COX-2 i... | 1,600 |
1,438 | 1,438 | 14,147,143 | 1,617 | A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capab... | 1-9. (canceled) 10. A method for providing a continuing and persistent antimicrobial against planktonic microorganisms and biofilms in the area of an open wound, said method comprising applying a substantially anhydrous hydrogen form of a cation exchange resin to said wound. 11. The method of claim 10, wherein said res... | A composition and method useful in promoting healing of a bleeding wound site. The composition preferably includes a substantially anhydrous acid form of a cation exchange resin, which when applied over blood, provides an antimicrobial against planktonic microorganisms and biofilms in the wound. The resin is also capab... | 1,600 |
1,439 | 1,439 | 15,450,233 | 1,658 | The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and imp... | 1.-35. (canceled) 36. A method for preparing a coated nanoparticle, the method comprising the following steps:
a) providing a nanoparticle comprising a complex of a nucleic acid and a polymeric carrier molecule according to generic formula (I):
L-P1—S—[S—P2—S]n—S—P3-L
wherein, P1 and P3 are different or identical to... | The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and imp... | 1,600 |
1,440 | 1,440 | 15,378,447 | 1,658 | Methods for shaping tissue matrices are provided. The methods can be used to produce shaped tissue products that retain desired biologic properties without using chemical crosslinking agents. | 1. A method for shaping a tissue matrix to support a breast implant, comprising:
selecting a collagen-containing tissue matrix; partially dehydrating the tissue matrix; applying mechanical forces to the tissue matrix to form a cup shape; and exposing the tissue matrix while partially dehydrated to ionizing radiation to... | Methods for shaping tissue matrices are provided. The methods can be used to produce shaped tissue products that retain desired biologic properties without using chemical crosslinking agents.1. A method for shaping a tissue matrix to support a breast implant, comprising:
selecting a collagen-containing tissue matrix; p... | 1,600 |
1,441 | 1,441 | 15,763,920 | 1,612 | A personal wash composition which provides an effective antimicrobial benefit against fungi, gram positive and gram negative bacteria, which composition comprises: a) from 0.1% to 10 wt % betaine surfactant, b) from 0.1% to 5.0 wt % lactic acid, c) from 0.1% to 20 wt % polyhydric C 2 -C 6 alcohol, d) from 0% to 10 wt ... | 1. A personal wash composition comprising:
from 0.1% to 10 wt % betaine surfactant; from 0.1% to 5.0 wt % lactic acid; from 0.1% to 20 wt % polyhydric C2-C6 alcohol; from 0% to 10 wt % alkyl polyethoxy carboxylate; from 0% to 10 wt % alkyl polyethoxy amides; greater than 8 wt % alkyl ether sulphate; water; a pH of 3.8-... | A personal wash composition which provides an effective antimicrobial benefit against fungi, gram positive and gram negative bacteria, which composition comprises: a) from 0.1% to 10 wt % betaine surfactant, b) from 0.1% to 5.0 wt % lactic acid, c) from 0.1% to 20 wt % polyhydric C 2 -C 6 alcohol, d) from 0% to 10 wt ... | 1,600 |
1,442 | 1,442 | 12,898,307 | 1,641 | Microfluidic devices may be fabricated from thermoplastics using, for example, hot embossing techniques. In some embodiments, the devices feature non-uniform surface modifications. | 1. A microfluidic device, comprising:
a thermoplastic polymer structure defining therein (i) first and second microchannels, and (ii) a chamber laterally separating and fluidically coupling the first and second microchannels; and a three-dimensional scaffold contained in the chamber. 2. The device of claim 1, wherein p... | Microfluidic devices may be fabricated from thermoplastics using, for example, hot embossing techniques. In some embodiments, the devices feature non-uniform surface modifications.1. A microfluidic device, comprising:
a thermoplastic polymer structure defining therein (i) first and second microchannels, and (ii) a cham... | 1,600 |
1,443 | 1,443 | 13,205,899 | 1,632 | Methods, mixtures, and kits related to treating tissue are provided. The methods, mixtures, and kits can include an acellular tissue matrix, a polymer, and a solvent and may be capable of producing tissue scaffolds. The tissue scaffolds may be able to form a stable, three-dimensional shape in situ and elicit a limited ... | 1. A method comprising:
providing a particulate acellular tissue matrix (ATM) and a solution comprising a polymer dissolved in a solvent; mixing the solution with the particulate ATM to create a mixture; and placing the mixture in contact with an aqueous media to allow the solvent to diffuse from the mixture to form a ... | Methods, mixtures, and kits related to treating tissue are provided. The methods, mixtures, and kits can include an acellular tissue matrix, a polymer, and a solvent and may be capable of producing tissue scaffolds. The tissue scaffolds may be able to form a stable, three-dimensional shape in situ and elicit a limited ... | 1,600 |
1,444 | 1,444 | 12,234,589 | 1,652 | Provided herein are methods for a robust production of isoprenoids via one or more biosynthetic pathways. Also provided herein are nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. Also provided herein are fermentation methods for high productivity of ... | 1. A method for producing an isoprenoid compound comprising:
(a) obtaining a plurality of host cells that are capable of making the isoprenoid compound comprising a chromosomally integrated heterologous nucleic acid sequence encoding an enzyme of the MEV or DXP pathway; (b) culturing the host cells in a medium under co... | Provided herein are methods for a robust production of isoprenoids via one or more biosynthetic pathways. Also provided herein are nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. Also provided herein are fermentation methods for high productivity of ... | 1,600 |
1,445 | 1,445 | 15,133,206 | 1,618 | There is provided a method of producing a mixed metal compound that includes at least Mg 2+ and at least Fe 3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 Å) comprising the steps of: (a) combining a Mg 2+ salt and a Fe 3+ salt with Na 2 CO 3 and NaOH to... | 1. A method of producing a mixed metal compound comprising
at least Mg2+ and at least Fe3+ having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 Å) comprising the steps of:
(a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein t... | There is provided a method of producing a mixed metal compound that includes at least Mg 2+ and at least Fe 3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 Å) comprising the steps of: (a) combining a Mg 2+ salt and a Fe 3+ salt with Na 2 CO 3 and NaOH to... | 1,600 |
1,446 | 1,446 | 12,344,361 | 1,615 | The present invention relates to biocompatible protein-based particles and their methods of preparation and use. More specifically the present invention relates protein-based particles including protein matrix, spread matrix and/or biocoacervate materials derived from one or more biocompatible purified proteins combine... | 1. A method of treating or enhancing the function of a spinal disc comprising:
administering a plurality of particles to the spinal disc or the surrounding fluid, space, tissue or bone of the spinal disc, said particles comprising one or more protein-based biomaterials at least partially produced from one or more bioco... | The present invention relates to biocompatible protein-based particles and their methods of preparation and use. More specifically the present invention relates protein-based particles including protein matrix, spread matrix and/or biocoacervate materials derived from one or more biocompatible purified proteins combine... | 1,600 |
1,447 | 1,447 | 16,494,902 | 1,639 | Systems, methods and compositions provided herein relate to the preparation of nucleic acid libraries. Some embodiments include the preparation of nucleic acid libraries by ligation of single-stranded nucleic acids. | 1. A method of preparing a nucleic acid library, comprising:
(a) obtaining a plurality of nucleic acids, wherein the plurality of nucleic acids is single-stranded nucleic acids; (b) dephosphorylating the 5′ ends of the single-stranded nucleic acids; (c) ligating a first adaptor to the 3′ ends of the single-stranded nuc... | Systems, methods and compositions provided herein relate to the preparation of nucleic acid libraries. Some embodiments include the preparation of nucleic acid libraries by ligation of single-stranded nucleic acids.1. A method of preparing a nucleic acid library, comprising:
(a) obtaining a plurality of nucleic acids, ... | 1,600 |
1,448 | 1,448 | 13,764,548 | 1,651 | A flow cytometry system ( 1 ) for sorting haploid cells, specifically irradiatable sperm cells, with an intermittingly punctuated radiation emitter ( 56 ). Embodiments include a beam manipulator ( 21 ) and even split radiation beams directed to multiple nozzles ( 5 ). Differentiation of sperm characteristics with incre... | 1-231. (canceled) 232. A flow cytometry system for sorting sperm comprising:
a) a nozzle for producing a stream comprising stained sperm cells in a sample and sheath fluid; b) a pulsed laser for exciting stained sperm cells in the stream; c) a detection system for detecting the emitted fluorescence of stained sperm cel... | A flow cytometry system ( 1 ) for sorting haploid cells, specifically irradiatable sperm cells, with an intermittingly punctuated radiation emitter ( 56 ). Embodiments include a beam manipulator ( 21 ) and even split radiation beams directed to multiple nozzles ( 5 ). Differentiation of sperm characteristics with incre... | 1,600 |
1,449 | 1,449 | 15,173,753 | 1,658 | Provided are processes of functionalizing a microparticle that include reacting a microparticle expressing a carboxylic acid with a functionalization linker including the structure N-L 1 -A where N is a free amine, L 1 is a linker, and A is an azide and an alkyne terminated group, to form a functional group terminated... | 1. A process of functionalizing a microparticle comprising:
reacting a microparticle expressing a carboxylic acid with a functionalization linker comprising N-L1-A where N is a free amine, L1 is a linker, and A is an azide or an alkyne terminated group, to form a functional group terminated microparticle; forming a fun... | Provided are processes of functionalizing a microparticle that include reacting a microparticle expressing a carboxylic acid with a functionalization linker including the structure N-L 1 -A where N is a free amine, L 1 is a linker, and A is an azide and an alkyne terminated group, to form a functional group terminated... | 1,600 |
1,450 | 1,450 | 14,414,936 | 1,635 | Disclosed herein are methods of discovering and validating select endophenotypes encompassing tumorigenic cancer stem cells. | 1. A method of assessing the tumorigenic potential of individual tumor populations in a population of cancer cells comprising:
a) isolating a sample from the subject comprising the population of cancer cells; b) separating individual tumor populations in the population of cancer cells from each other based on different... | Disclosed herein are methods of discovering and validating select endophenotypes encompassing tumorigenic cancer stem cells.1. A method of assessing the tumorigenic potential of individual tumor populations in a population of cancer cells comprising:
a) isolating a sample from the subject comprising the population of c... | 1,600 |
1,451 | 1,451 | 16,644,279 | 1,611 | The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation. | 1. A formulation in the form of an aqueous suspension comprising calcium citrate and isomalt. 2. The formulation in the form of an aqueous suspension according to claim 1, wherein calcium citrate is calcium citrate tetrahydrate. 3. The formulation in the form of an aqueous suspension according to claim 1, further compr... | The present invention relates to a formulation in the form of an aqueous suspension comprising calcium citrate. Said formulation exhibits excellent stability and compliance and finds use in calcium supplementation in subjects in need of such supplementation.1. A formulation in the form of an aqueous suspension comprisi... | 1,600 |
1,452 | 1,452 | 16,100,369 | 1,644 | Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts (e.g., at least 97%) of a long-chain fatty acid ester. Also disc... | 1. A method of reducing subvisible and visible particle formation in a drug product, the method comprising:
including at least 100 mg/mL of an IgG antibody in the drug product; and including a mixture of fatty acid esters of polyoxyethylene sorbitan in the drug product, wherein a content of oleic acid esters in the mix... | Biopharmaceutical compositions and drug products disclosed herein exhibit reduced amounts of subvisible particle formation. Compositions and drug products disclosed herein comprise a protein and a surfactant or stabilizer including high percentage amounts (e.g., at least 97%) of a long-chain fatty acid ester. Also disc... | 1,600 |
1,453 | 1,453 | 15,292,021 | 1,631 | Systems and methods are presented that allow for predicting treatment response of a tumor to a checkpoint inhibitor. In one exemplary aspect, the treatment response is directly associated with a relatively high number of patient- and tumor-specific immunologically visible neoepitopes. Specific mutational patterns in th... | 1. A method of improving treatment of a cancer using immunotherapy, comprising:
obtaining from a patient omics data from a tumor tissue and a matched normal tissue, and using the omics data to determine a plurality of missense based patient- and tumor-specific neoepitopes; filtering the neoepitopes to obtain HLA-matche... | Systems and methods are presented that allow for predicting treatment response of a tumor to a checkpoint inhibitor. In one exemplary aspect, the treatment response is directly associated with a relatively high number of patient- and tumor-specific immunologically visible neoepitopes. Specific mutational patterns in th... | 1,600 |
1,454 | 1,454 | 14,788,908 | 1,617 | The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophil... | 1. A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system. 2. The pharmaceutical composition of claim 1, wherein at least ab... | The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophil... | 1,600 |
1,455 | 1,455 | 16,011,118 | 1,658 | compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension. | 1. A compound of formula (I)
wherein:
(i) X is —CH and R1=H; or
X is N and R1 is H, (C1-12)alkyl, (C4-C14)aralkyl, SO2(C3-C7) aryl, —SO2(C1-12)alkyl, —SO2aralkyl, —CO(C1-12)alkyl, CO(C4-C14)aralkyl, or —C(═NH)NH2;
(ii) R2 is H or —CH3; and R3 is H, —NH2, —NHalkyl, NHaralkyl, —NHCOalkyl, —NHSO2aryl, or —NH(C═... | compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.1. A compound of formula (I)
wherein:
(i) X is —CH and R1=H; or
X is N and R1 is H, (C1-12)alkyl, (C4-C14)aralkyl, SO2(C3-C7) aryl, —SO2(C1-12)alkyl, —SO2aralkyl, —CO(C1-12)alky... | 1,600 |
1,456 | 1,456 | 16,176,458 | 1,618 | The present invention relates to customized implants for bone replacement that are prepared from poly(ether ketone ketone) or PEKK, and to a computer-based imaging and rapid prototyping (RP)-based manufacturing method for the design and manufacture of these customized implants. The PEKK customized implants made using r... | 1. A method of forming an implant for use in a mammal, the method comprising the steps of:
providing a model of an implant; providing a powder comprising polyetherketoneketone (PEKK) and excluding calcium phosphate; forming the implant by selective laser sintering the powder in accordance with the model of the implant.... | The present invention relates to customized implants for bone replacement that are prepared from poly(ether ketone ketone) or PEKK, and to a computer-based imaging and rapid prototyping (RP)-based manufacturing method for the design and manufacture of these customized implants. The PEKK customized implants made using r... | 1,600 |
1,457 | 1,457 | 15,849,129 | 1,617 | Disclosed are oral care compositions, for example dentifrice compositions, comprising an oral care composition comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and at least one amino acid capable of chelating the metal oxide. The compositi... | 1. An oral care composition comprising:
an orally acceptable vehicle; a source of metal oxide particles, wherein said metal oxide particles have a median particle size of from 1 to 7 microns;
one or more amino acids capable of chelating said metal oxide particles, wherein the metal oxide comprises at least one metal o... | Disclosed are oral care compositions, for example dentifrice compositions, comprising an oral care composition comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and at least one amino acid capable of chelating the metal oxide. The compositi... | 1,600 |
1,458 | 1,458 | 15,749,541 | 1,612 | Described herein are oral care compositions comprising a basic amino acid; a combination of zinc ion sources; and a thickening system comprising a nonionic cellulose ether having a viscosity, measured at 2% in water at 25° C., of 4500 to 7500 cps; and a polysaccharide gum; along with methods of making and using same. | 1. An oral care composition comprising:
a. a basic amino acid in free or salt form wherein the basic amino acid is selected from arginine, lysine, and a combination thereof, b. a combination of zinc ion sources: and c. a thickening system comprising:
i. from about 0.1 wt. % to about 1 wt. % of a nonionic cellulose ethe... | Described herein are oral care compositions comprising a basic amino acid; a combination of zinc ion sources; and a thickening system comprising a nonionic cellulose ether having a viscosity, measured at 2% in water at 25° C., of 4500 to 7500 cps; and a polysaccharide gum; along with methods of making and using same.1.... | 1,600 |
1,459 | 1,459 | 15,125,932 | 1,617 | The present invention relates to an implantable paste comprising bioactive glass powder having a size distribution of 0.5-45 μm, bioactive glass granules having a size distribution between 100 and 4000 μm, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight... | 1. An implantable paste comprising
(a) bioactive glass powder having a size distribution of 0.5-45 μm in an amount of 10-30 wt-% of the total weight of the bioactive glass, (b) bioactive glass granules having a size distribution between 100 and 4000 μm in an amount of 90-70 wt-% of the total weight of the bioactive gla... | The present invention relates to an implantable paste comprising bioactive glass powder having a size distribution of 0.5-45 μm, bioactive glass granules having a size distribution between 100 and 4000 μm, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight... | 1,600 |
1,460 | 1,460 | 15,318,310 | 1,611 | The present invention relates to a biphasic composition or consisting of alcohol, a polar compound, a fragrance and a branched hydrocarbon. | 1. Biphasic composition comprising or consisting of alcohol, a polar compound, a fragrance and a branched hydrocarbon. 2. Biphasic composition according to claim 1, wherein the biphasic composition comprises or consists of:
20 to 75 wt % alcohol; 0.5 to 30 wt % polar compound; 1 to 50 wt % fragrance and 5 to 60 wt % br... | The present invention relates to a biphasic composition or consisting of alcohol, a polar compound, a fragrance and a branched hydrocarbon.1. Biphasic composition comprising or consisting of alcohol, a polar compound, a fragrance and a branched hydrocarbon. 2. Biphasic composition according to claim 1, wherein the biph... | 1,600 |
1,461 | 1,461 | 15,104,149 | 1,649 | Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the c... | 1-45. (canceled) 46. A method for determining the progression and/or the prognosis of a neurocognitive disorder in a subject, said method comprises the steps of:
a) providing a sample comprising a tissue sample or a body fluid obtained from the subject having a neurocognitive disorder or symptoms thereof at a test time... | Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the c... | 1,600 |
1,462 | 1,462 | 15,855,162 | 1,658 | The present invention relates to a method for purification of viral vectors, more closely it relates to purification of viral vectors from producer cells by using a single automated process. The method comprises the following steps: a) adding producer cells and cell lysis buffer to a processing container; b) mixing sai... | 1. A method for isolation of viral vectors comprising a gene of interest following production by cultivation of said viral vectors in producer cells, comprising the following steps in a continuous workflow: a) adding producer cells and cell lysis buffer to a processing container; b) mixing said producer cells and cell ... | The present invention relates to a method for purification of viral vectors, more closely it relates to purification of viral vectors from producer cells by using a single automated process. The method comprises the following steps: a) adding producer cells and cell lysis buffer to a processing container; b) mixing sai... | 1,600 |
1,463 | 1,463 | 15,420,888 | 1,611 | The present invention relates to a topcoat composition for long-wear lip compositions comprising at least one silicone film-forming agent, as well as to systems, kits and methods of treating, making-up and enhancing the appearance of lips, including a long-wear lip composition comprising at least one silicone film-form... | 1. (canceled) 2. (canceled) 3. A kit comprising (1) a long-wear lip composition comprising at least one silicone film-forming agent, and (2) a topcoat composition consisting essentially of at least one phenylated silicone oil and at least one wax. 4. A kit comprising (1) a long-wear lip composition comprising at least ... | The present invention relates to a topcoat composition for long-wear lip compositions comprising at least one silicone film-forming agent, as well as to systems, kits and methods of treating, making-up and enhancing the appearance of lips, including a long-wear lip composition comprising at least one silicone film-form... | 1,600 |
1,464 | 1,464 | 15,565,226 | 1,658 | The present invention relates to the cosmetic use of a composition including, as the active agent, 0.1 to 1 μM of a synthetic peptide of sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 or one of the salts thereof in a physiologically suitable medium, in order to reduce or delay the appearance of cell senescence and signs of s... | 1. A method for reducing or delaying the appearance of cellular senescence and signs of skin aging selected from thinning of the skin, sagging, loss of moisture, skin atony, deep wrinkles and fine lines, loss of firmness and tone, dermal atrophy with the exception of pigmentary anomalies of the skin, the method compris... | The present invention relates to the cosmetic use of a composition including, as the active agent, 0.1 to 1 μM of a synthetic peptide of sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 or one of the salts thereof in a physiologically suitable medium, in order to reduce or delay the appearance of cell senescence and signs of s... | 1,600 |
1,465 | 1,465 | 16,225,823 | 1,612 | The present invention relates to an oral care composition with a high water content which has improved robustness towards microbial challenge. The oral care composition includes compositions comprising from 0.125 wt % to 0.75 wt % of a water soluble source of stannous ions, wherein the composition comprises at least 50... | 1. An aqueous oral care composition comprising from 0.125 wt % to 0.75 wt % of a water soluble source of stannous ions, wherein the composition comprises at least 50 wt % water and wherein the source of stannous ions is selected from the group consisting of stannous chloride, stannous pyrophosphate, stannous formate, s... | The present invention relates to an oral care composition with a high water content which has improved robustness towards microbial challenge. The oral care composition includes compositions comprising from 0.125 wt % to 0.75 wt % of a water soluble source of stannous ions, wherein the composition comprises at least 50... | 1,600 |
1,466 | 1,466 | 14,524,115 | 1,699 | A method for obtaining MNCs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the sep... | 1. A method for obtaining mononuclear cells and preparing the mononuclear cells for photopheresis with a separation device comprising:
a) separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets; b) collecting a targeted number of mononuclear cells in a suspension includi... | A method for obtaining MNCs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the sep... | 1,600 |
1,467 | 1,467 | 11,545,986 | 1,634 | Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv,... | 1. A method of detecting the presence of a methicillin-resistant Staphylococcus aureus (MRSA) strain in a sample comprising nucleic acids, wherein the MRSA strain comprises an SCCmec insert comprising a mecA gene inserted in bacterial nucleic acids, and wherein the insertion of said SSCmec insert in the bacterial nucle... | Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv,... | 1,600 |
1,468 | 1,468 | 16,520,936 | 1,631 | A method of administering insulin includes receiving subcutaneous information for a patient at a computing device and executing a subcutaneous outpatient program for determining recommended insulin dosages. The subcutaneous outpatient program includes obtaining blood glucose data of the patient from a glucometer in com... | 1. A method comprising:
receiving, at data processing hardware of a patient device, glucose data of a patient associated with the patient device, the glucose data including glucose measurements of the patient and glucose times associated with the glucose measurements; transmitting, by the data processing hardware, the ... | A method of administering insulin includes receiving subcutaneous information for a patient at a computing device and executing a subcutaneous outpatient program for determining recommended insulin dosages. The subcutaneous outpatient program includes obtaining blood glucose data of the patient from a glucometer in com... | 1,600 |
1,469 | 1,469 | 15,919,273 | 1,613 | A consumer product composition comprises a consumer product adjunct ingredient, a microcapsule, and chitosan disposed on an outer surface of the microcapsule. The chitosan has a weight average molecular weight of at least about 100 kDa and/or a degree of deacetylation of at least about 60%. The microcapsule comprises a... | 1. A consumer product composition comprising
a consumer product adjunct ingredient; microcapsules comprising a shell material encapsulating a core material, said core material being disposed within said shell material, wherein said shell material comprises a polyacrylate polymer and said core material comprises a benef... | A consumer product composition comprises a consumer product adjunct ingredient, a microcapsule, and chitosan disposed on an outer surface of the microcapsule. The chitosan has a weight average molecular weight of at least about 100 kDa and/or a degree of deacetylation of at least about 60%. The microcapsule comprises a... | 1,600 |
1,470 | 1,470 | 14,738,551 | 1,643 | The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly... | 1. A method of treating a mammal for removal or destruction of unwanted cellular proliferations comprising administering to the mammal a therapeutically effective amount of an isolated peptide comprising the amino acid sequence in SEQ ID NO. 66 (Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), in c... | The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors using compounds based on small peptides in combination with additional active agent(s). The method includes, but is not limited to, administering the compounds intramuscularly... | 1,600 |
1,471 | 1,471 | 15,845,608 | 1,615 | Disclosed is a stable anhydrous dispersion comprising a dispersed sugar phase comprising granulated sugar and powdered sugar, wherein the dispersion comprises 55% to 75% by weight, based on the total weight of the composition, of a combination of granulated sugar and powdered sugar, and a continuous oil phase, wherein ... | 1.-28. (canceled) 29. A method of treating skin, the method comprising topically applying to skin in need thereof a stable anhydrous dispersion, wherein topical application of the anhydrous dispersion treats the skin, and wherein the anhydrous dispersion consists essentially of:
(a) a dispersed sugar phase comprising g... | Disclosed is a stable anhydrous dispersion comprising a dispersed sugar phase comprising granulated sugar and powdered sugar, wherein the dispersion comprises 55% to 75% by weight, based on the total weight of the composition, of a combination of granulated sugar and powdered sugar, and a continuous oil phase, wherein ... | 1,600 |
1,472 | 1,472 | 14,905,539 | 1,629 | A pharmaceutical composition for inducing reactivation of latent provirus in an HIV infected cell includes an ESR-1 antagonist or an ESR-1 coactivator antagonist and a pharmaceutically acceptable carrier. | 1-15. (canceled) 16. A method for inducing activation of latent provirus expression in an HIV infected cell, the method comprising:
contacting the cell with an effective amount of a pharmaceutical composition, the pharmaceutical composition comprising an ESR-1 antagonist or an ESR-1 coactivator antagonist, an activator... | A pharmaceutical composition for inducing reactivation of latent provirus in an HIV infected cell includes an ESR-1 antagonist or an ESR-1 coactivator antagonist and a pharmaceutically acceptable carrier.1-15. (canceled) 16. A method for inducing activation of latent provirus expression in an HIV infected cell, the met... | 1,600 |
1,473 | 1,473 | 15,660,928 | 1,619 | A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves trans... | 1. A method for delivering a therapeutic agent to a subject, comprising:
providing a transdermal delivery system comprised of a therapeutic agent and a reservoir comprising the therapeutic agent, wherein the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii)... | A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves trans... | 1,600 |
1,474 | 1,474 | 14,525,951 | 1,646 | The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as IL-1β and TNF... | 1. A method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject an effective dose of an anti-interleukin 12/23 antibody. 2. The method of claim 1, wherein the anti-interleukin 12/23 antibody is administered in a fully humanized antibody. 3. The... | The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject. Oral administration of ustekinumab also is useful in a method of decreasing innate inflammatory cytokines, such as IL-1β and TNF... | 1,600 |
1,475 | 1,475 | 16,851,999 | 1,628 | Disclosed herein are methods of for treating hyperammonemia in a patient having renal impairment, comprising administering carglumic acid to said patient at a reduced daily dosage. | 1. A method for treating hyperammonemia in a patient in need thereof, comprising:
identifying the patient as having moderate renal impairment; and administering carglumic acid to the patient at a daily dosage of 5 mg/kg/day to 125 mg/kg/day divided into two to four doses. 2. The method of claim 1, wherein the patient h... | Disclosed herein are methods of for treating hyperammonemia in a patient having renal impairment, comprising administering carglumic acid to said patient at a reduced daily dosage.1. A method for treating hyperammonemia in a patient in need thereof, comprising:
identifying the patient as having moderate renal impairmen... | 1,600 |
1,476 | 1,476 | 14,807,989 | 1,619 | The present invention provides methods for preparing an absorbent antimicrobial wound dressing which comprise steps of (a) preparing an antimicrobial coating composition by mixing an antimicrobial agent and one or more polymers in a solvent system that comprises a non-aqueous solvent, (b) contacting the antimicrobial c... | 1. A method of preparing an absorbent antimicrobial wound dressing comprising:
(a) preparing an antimicrobial coating composition by mixing an antimicrobial agent and one or more polymers in a solvent system that comprises a non-aqueous solvent; (b) contacting the antimicrobial coating composition of step (a) with a wo... | The present invention provides methods for preparing an absorbent antimicrobial wound dressing which comprise steps of (a) preparing an antimicrobial coating composition by mixing an antimicrobial agent and one or more polymers in a solvent system that comprises a non-aqueous solvent, (b) contacting the antimicrobial c... | 1,600 |
1,477 | 1,477 | 15,769,192 | 1,645 | The present invention pertains to a vaccine comprising inactivated Lawsonia intracellularis antigen for intradermal administration to an animal that has maternally derived antibodies directed against Lawsonia intracellularis , for use in a method to protect the animal against a disorder arising from an infection wit... | 1. (canceled) 2. (canceled) 3. (canceled) 4. (canceled) 5. (canceled) 6. A method for protecting an animal that has maternally derived antibodies against Lawsonia intracellularis, against a disorder arising from an infection with Lawsonia intracellularis, by intradermally administering a vaccine comprising inactivated ... | The present invention pertains to a vaccine comprising inactivated Lawsonia intracellularis antigen for intradermal administration to an animal that has maternally derived antibodies directed against Lawsonia intracellularis , for use in a method to protect the animal against a disorder arising from an infection wit... | 1,600 |
1,478 | 1,478 | 15,738,954 | 1,615 | The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on th... | 1. A particle having at least one surface and an agent immobilized on the surface, wherein:
the agent selectively binds to a target that is a first member of a specific binding pair; and binding of the target to the particle inhibits the interaction of the target with a second member of the specific binding pair. 2. A ... | The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on th... | 1,600 |
1,479 | 1,479 | 13,981,229 | 1,619 | The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient... | 1. A medical device containing a separately prepared freeze-dried cake composition comprising aripiprazole as an active ingredient in a storage container whose inner wall is treated with silicone, wherein there is a space between the inner wall of the storage container and the cake composition. 2. The medical device co... | The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient... | 1,600 |
1,480 | 1,480 | 16,289,775 | 1,612 | The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a lipos... | 1. A liposome having a lipid ingredient and encapsulating a therapeutic agent, wherein a mass ratio of said therapeutic agent to lipid ingredient is about 1:5 to 1:8, and wherein the liposome has osmolality internal to the liposome in a range of 340-440 mO/kg. 2. A formulation comprising a liposome, said liposome havin... | The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a lipos... | 1,600 |
1,481 | 1,481 | 15,646,601 | 1,619 | Provided herein relates to methods and compositions for preparing a silk microsphere and the resulting silk microsphere. In some embodiments, the methods and compositions described herein are all aqueous, which can be used for encapsulating an active agent in a silk microsphere, while maintaining activity of the active... | 1.-75. (canceled) 76. A method of preparing a silk microsphere, the method comprising:
atomizing a silk solution to form silk microspheres with a diameter of at least 50 μm; freezing the silk microspheres, and lyophilizing the silk microspheres to form porous silk microspheres, wherein the porous silk microspheres have... | Provided herein relates to methods and compositions for preparing a silk microsphere and the resulting silk microsphere. In some embodiments, the methods and compositions described herein are all aqueous, which can be used for encapsulating an active agent in a silk microsphere, while maintaining activity of the active... | 1,600 |
1,482 | 1,482 | 15,832,190 | 1,619 | The present disclosure provides dry shampoo compositions effective for cleaning hair and also moisturizing hair. The dry shampoo compositions can comprise a starch component, a conditioning agent, and optional further ingredients, such as propellants and fragrances. | 1. A dry shampoo composition, comprising:
a starch material; a hydrophobic emollient; and optionally a propellant. 2. The dry shampoo composition of claim 1, wherein the dry shampoo is substantially free of silicones. 3. The dry shampoo composition of claim 1, wherein the dry shampoo is substantially free of petroleum ... | The present disclosure provides dry shampoo compositions effective for cleaning hair and also moisturizing hair. The dry shampoo compositions can comprise a starch component, a conditioning agent, and optional further ingredients, such as propellants and fragrances.1. A dry shampoo composition, comprising:
a starch mat... | 1,600 |
1,483 | 1,483 | 15,773,044 | 1,635 | Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming ... | 1. A use of a composition comprising a mycotoxin-deactivating aptamer for inhibiting the toxicity of mycotoxin and preventing absorption of active mycotoxin in a gastrointestinal tract. 2. The use as claimed in claim 1, said composition further comprising one or more of: a mycotoxin-specific antibody, a mycotoxin-adsor... | Mycotoxin-deactivating aptamers, especially DNA aptamers, bind to mycotoxins in feed and feed ingredients resulting in the reduction or elimination of toxic and carcinogenic effects of mycotoxins. The invention also discloses a composition comprising a mycotoxin-deactivating aptamer, a binding agent, a biotransforming ... | 1,600 |
1,484 | 1,484 | 16,387,185 | 1,653 | The present disclosure relates to testing, analysis and treatment of an environment, wherein one or more baseline(s) is established for the environment. Systems and methods for detecting, treating, comparing and testing for mold, mold spores and mold fragments physically present or in the air of an environment are disc... | 1. A method for remediating the effect of mold in an indoor environment, comprising:
detecting the physical presence of mold, mold spores and mold fragments; sampling in real time for both physical and airborne mold, mold spores and mold fragments by using adhesive tape for physical surfaces located in the environment,... | The present disclosure relates to testing, analysis and treatment of an environment, wherein one or more baseline(s) is established for the environment. Systems and methods for detecting, treating, comparing and testing for mold, mold spores and mold fragments physically present or in the air of an environment are disc... | 1,600 |
1,485 | 1,485 | 16,696,095 | 1,617 | Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of d... | 1.-12. (canceled) 13. A method of treating a peripheral nerve injury in a subject comprising administering to the subject an effective amount of a composition comprising 4-aminopyridine (4-AP) and a pharmaceutically acceptable carrier, wherein administration promotes remyelination of the peripheral nerve in the subject... | Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of d... | 1,600 |
1,486 | 1,486 | 14,803,677 | 1,656 | This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. | 1.-35. (canceled) 36. A method for the treatment of hemophilia in a patient who has already developed factor VIII inhibitory antibodies comprising administering a therapeutically effective amount of a pharmaceutical composition of a conjugate having factor VIII procoagulant activity comprising a functional factor VIII ... | This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.1.-35. (canceled) 36. A ... | 1,600 |
1,487 | 1,487 | 15,376,298 | 1,651 | Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for promoting and/or accelerating myelination in a target subject via administering the nutritional composition containing dietary butyrate to the target subject. | 1. A nutritional composition comprising:
a carbohydrate source; a protein equivalent source; a fat or lipid source; and dietary butyrate. 2. The nutritional composition of claim 1, wherein the nutritional composition further comprise a probiotic. 3. The nutritional composition of claim 1, wherein 1% to 99% of the prote... | Provided are nutritional compositions containing dietary butyrate. Further disclosed are methods for promoting and/or accelerating myelination in a target subject via administering the nutritional composition containing dietary butyrate to the target subject.1. A nutritional composition comprising:
a carbohydrate sourc... | 1,600 |
1,488 | 1,488 | 13,336,477 | 1,662 | The invention relates to a celery plant ( Apium graveolens L. dulce) carrying a genetic determinant that leads to short leaf blades and/or a more uniform distribution of stem lengths as compared to celery plants not carrying the genetic determinant, wherein said determinant is obtainable by introgression from a plant ... | 1. Celery plant (Apium graveolens L. dulce) carrying a genetic determinant that lead to short leaf blades and/or a more uniform distribution of stem lengths as compared to celery plants not carrying the genetic determinant, wherein said determinant is obtainable by introgression from a plant grown from seed of which a ... | The invention relates to a celery plant ( Apium graveolens L. dulce) carrying a genetic determinant that leads to short leaf blades and/or a more uniform distribution of stem lengths as compared to celery plants not carrying the genetic determinant, wherein said determinant is obtainable by introgression from a plant ... | 1,600 |
1,489 | 1,489 | 15,600,299 | 1,658 | An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of... | 1. An intrauterine device comprising at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material having dispersed therein between 10 and 60 v/v % of at least one particulate material that obstructs the diffusion of the pharmaceutically active ingredient... | An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of... | 1,600 |
1,490 | 1,490 | 15,478,352 | 1,619 | A shampoo composition having from about 0.025% to about 0.25% histidine, by weight of the shampoo composition; from about 2% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; and a gel matrix having from about 0.1% to about 20% of one or more fatty alcohols, by weight of the gel m... | 1) A shampoo composition comprising:
a. from about 0.025% to about 0.25% histidine, by weight of the shampoo composition; b. from about 2% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; and c. a gel matrix comprising:
i. from about 0.1% to about 20% of one or more fatty alcohol... | A shampoo composition having from about 0.025% to about 0.25% histidine, by weight of the shampoo composition; from about 2% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; and a gel matrix having from about 0.1% to about 20% of one or more fatty alcohols, by weight of the gel m... | 1,600 |
1,491 | 1,491 | 13,792,361 | 1,627 | The described invention provides a method for treating a behavioral deficit, such as irritability and stereotypic/repetitive behaviors, in a subject with autism spectrum disorder by administering a composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically a... | 1. A method for treating a behavioral deficit in a subject with autism spectrum disorder characterized by glutamatergic dysfunction and redox imbalance, the method comprising:
(a) administering to the subject a pharmaceutical composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcyste... | The described invention provides a method for treating a behavioral deficit, such as irritability and stereotypic/repetitive behaviors, in a subject with autism spectrum disorder by administering a composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically a... | 1,600 |
1,492 | 1,492 | 16,368,907 | 1,627 | Methods of treating eye disorders with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Methods of treating eye disorders with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic... | 1. A method of treating an eye disorder comprising administering to a patient in need thereof (1 S,3 S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount of from 0.01 mg to 500 mg, wherein the method provides improvement in one or more symptoms of e... | Methods of treating eye disorders with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Methods of treating eye disorders with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic... | 1,600 |
1,493 | 1,493 | 14,483,483 | 1,743 | A non-pneumatic tire includes a plurality of springs. Each spring comprises a first end portion, a second end portion, and an arching middle portion. Each spring is interwoven with at least one other spring thereby forming a toroidal structure extending about an entire circumference of the non-pneumatic tire. The toroi... | 1. A method for constructing a non-pneumatic tire comprises the steps of:
sliding a carcass ply structure into engagement with a bladder; seating a first circular bead of the carcass ply structure onto a mold; partially inflating the bladder to form a bulged carcass ply structure; pouring an elastomer into the mold; se... | A non-pneumatic tire includes a plurality of springs. Each spring comprises a first end portion, a second end portion, and an arching middle portion. Each spring is interwoven with at least one other spring thereby forming a toroidal structure extending about an entire circumference of the non-pneumatic tire. The toroi... | 1,700 |
1,494 | 1,494 | 14,665,835 | 1,799 | The invention relates mainly to an apparatus comprising a chamber for physically and/or chemically treating one or more samples or products, said apparatus comprising a door for introducing samples inside the apparatus chamber or bringing samples outside the apparatus, said apparatus comprising a membrane or film defin... | 1.-15. (canceled) 16. An apparatus comprising:
a disinfector including a chamber for receiving one or more samples or products and a door adapted for moving between a closed position and an open position for introducing the one or more samples or products inside the chamber or bringing the one or more samples or produc... | The invention relates mainly to an apparatus comprising a chamber for physically and/or chemically treating one or more samples or products, said apparatus comprising a door for introducing samples inside the apparatus chamber or bringing samples outside the apparatus, said apparatus comprising a membrane or film defin... | 1,700 |
1,495 | 1,495 | 14,075,555 | 1,735 | A blade for a gas turbine has a leading edge and a trailing edge, and an interior cavity, which is delimited by internal surfaces, for guiding cooling air therethrough. A multiplicity of turbulators or pins, which are formed on the wall, are arranged in a distributed manner in the region of the trailing edge and projec... | 1. A method for producing a blade for a gas turbine by a casting technique, the blade having a leading edge and a trailing edge, and an interior cavity, which is delimited by internal surfaces, for guiding cooling air therethrough, wherein for improving the transfer of heat between the wall of the blade and the cooling... | A blade for a gas turbine has a leading edge and a trailing edge, and an interior cavity, which is delimited by internal surfaces, for guiding cooling air therethrough. A multiplicity of turbulators or pins, which are formed on the wall, are arranged in a distributed manner in the region of the trailing edge and projec... | 1,700 |
1,496 | 1,496 | 13,242,014 | 1,797 | The invention is directed towards methods, compositions, and apparatus for accurately detecting the presence and amounts of contaminants in wastewater. The method comprises the steps of adding to a volume of wastewater at least one tracer molecule, observing the tracer for indications of particular contaminants, conduc... | 1. A method of accurately detecting the presence and amounts of specific contaminants in at least one liquid comprising the steps of:
providing a volume of liquid, conducting a method of contamination detection capable of measuring the amount of turbidity in the volume of liquid and inferring from that the amount of tu... | The invention is directed towards methods, compositions, and apparatus for accurately detecting the presence and amounts of contaminants in wastewater. The method comprises the steps of adding to a volume of wastewater at least one tracer molecule, observing the tracer for indications of particular contaminants, conduc... | 1,700 |
1,497 | 1,497 | 14,116,991 | 1,734 | The present invention provides a method for the fabrication of a steel sheet with a completely martensitic structure which has an average lath size of less than 1 micrometer and an average elongation factor of the laths is between 2 and 5. The elongation factor of a lath is defined as a maximum dimension divided by and... | 1-9. (canceled) 10. A method for the fabrication of steel sheet with a completely martensitic structure with an average lath size of less than 1 micrometer, an average elongation factor of the laths being between 2 and 5, an elongation factor of a lath having a maximum dimension 1max and a minimum dimension 1min being ... | The present invention provides a method for the fabrication of a steel sheet with a completely martensitic structure which has an average lath size of less than 1 micrometer and an average elongation factor of the laths is between 2 and 5. The elongation factor of a lath is defined as a maximum dimension divided by and... | 1,700 |
1,498 | 1,498 | 11,418,457 | 1,791 | A retorted liquid soup concentrate package (of about 70 to 100 g contents) expressible from the package when opened and dilutable with boiling or near boiling water (at a dilution ratio water/concentrate of from 1.9:1 to 2.5:1) to a lump free ready to eat soup form at at least 55° C. (preferably 60 to 65° C.) and a tar... | 1. A soup concentrate product comprising or including
a sealed container, a liquid including soup concentrate adapted to be diluted by boiling or near boiling water to a ready to serve soup form, the concentrate being within the container, wherein said concentrate is capable of being expressed, poured or otherwise r... | A retorted liquid soup concentrate package (of about 70 to 100 g contents) expressible from the package when opened and dilutable with boiling or near boiling water (at a dilution ratio water/concentrate of from 1.9:1 to 2.5:1) to a lump free ready to eat soup form at at least 55° C. (preferably 60 to 65° C.) and a tar... | 1,700 |
1,499 | 1,499 | 12,875,521 | 1,791 | A method for producing a processed meat product begins at the supplier, where whole muscle meat is reduced into whole muscle meat pieces and the pieces may be macerated to increase their surface area. Prior to shipment of the whole muscle meat from the supplier to the meat processing plant, the whole muscle meat pieces... | 1. A method for preparing a raw base material for use in a processed meat product, the method comprising:
at a meat packing plant, deboning whole muscle meat to thereby create boneless whole muscle meat having a surface area; increasing the surface area of the whole muscle meat at said meat packing plant; mixing an ini... | A method for producing a processed meat product begins at the supplier, where whole muscle meat is reduced into whole muscle meat pieces and the pieces may be macerated to increase their surface area. Prior to shipment of the whole muscle meat from the supplier to the meat processing plant, the whole muscle meat pieces... | 1,700 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.